ZA200604412B - Bacterial virulence factors and uses thereof - Google Patents
Bacterial virulence factors and uses thereofInfo
- Publication number
- ZA200604412B ZA200604412B ZA200604412A ZA200604412A ZA200604412B ZA 200604412 B ZA200604412 B ZA 200604412B ZA 200604412 A ZA200604412 A ZA 200604412A ZA 200604412 A ZA200604412 A ZA 200604412A ZA 200604412 B ZA200604412 B ZA 200604412B
- Authority
- ZA
- South Africa
- Prior art keywords
- virulence factors
- bacterial virulence
- bacterial
- factors
- virulence
- Prior art date
Links
- 230000007924 bacterial virulence factor Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Virology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51570303P | 2003-10-31 | 2003-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200604412B true ZA200604412B (en) | 2007-09-26 |
Family
ID=34549436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200604412A ZA200604412B (en) | 2003-10-31 | 2004-10-29 | Bacterial virulence factors and uses thereof |
Country Status (16)
Country | Link |
---|---|
US (2) | US8758771B2 (fr) |
EP (3) | EP2383287A1 (fr) |
JP (2) | JP5100122B2 (fr) |
KR (3) | KR101242445B1 (fr) |
CN (2) | CN101711861A (fr) |
AR (1) | AR050050A1 (fr) |
AU (2) | AU2004286002B2 (fr) |
BR (1) | BRPI0415816A (fr) |
CA (1) | CA2543763A1 (fr) |
MX (1) | MXPA06004858A (fr) |
NO (1) | NO20062361L (fr) |
NZ (1) | NZ547156A (fr) |
RU (2) | RU2465331C2 (fr) |
UA (1) | UA94206C2 (fr) |
WO (1) | WO2005042746A1 (fr) |
ZA (1) | ZA200604412B (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101711861A (zh) | 2003-10-31 | 2010-05-26 | 不列颠哥伦比亚大学 | 细菌毒力因子及其用途 |
US9107864B2 (en) * | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
US20090197249A1 (en) * | 2004-11-01 | 2009-08-06 | George Mason University | Compositions and methods for diagnosing colon disorders |
DK2016414T3 (en) * | 2006-05-05 | 2015-12-07 | Opexa Therapeutics | T-cell vaccine |
US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
ES2335177B1 (es) * | 2008-09-19 | 2011-02-28 | Archivel Farma, S.L. | Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis. |
US8241623B1 (en) | 2009-02-09 | 2012-08-14 | David Bermudes | Protease sensitivity expression system |
GB0909198D0 (en) * | 2009-05-28 | 2009-07-15 | Queen Mary & Westfield College | Methods and composition for treating NF-kappa B mediated disorders |
WO2011005587A1 (fr) * | 2009-06-24 | 2011-01-13 | University Of Dubuque | Compositions de vaccin et procédés d'utilisation pour protéger contre des maladies infectieuses |
WO2011007350A2 (fr) * | 2009-07-13 | 2011-01-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Agents immunomodulateurs et système de distribution ciblée sur un tissu pour ceux-ci pour le traitement de troubles liés à l'immunité |
EP2292799A1 (fr) * | 2009-08-11 | 2011-03-09 | Agence Française de Securité Sanitaire des Aliments | Analyse pour déterminer l'évaluation du risque moléculaire d'isolats de STEC |
US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US9408873B2 (en) | 2010-08-23 | 2016-08-09 | Kang Stem Biotech Co., Ltd. | Pharmaceutical composition comprising stem cells treated with NOD2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases |
RU2497541C1 (ru) * | 2012-07-20 | 2013-11-10 | федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почётного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Фармацевтическая композиция на основе лигандов паттерн-распознающих рецепторов, способ ее использования в качестве иммуностимулятора для лечения инфекций, вызванных бактериальными и вирусными патогенами, способ ее использования в качестве адъюванта в составе вакцин |
US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
US9579370B2 (en) | 2014-03-04 | 2017-02-28 | The Board Of Regents Of The University Of Texas System | Compositions and methods for enterohemorrhagic Escherichia coli (EHEC)vaccination |
US10226520B2 (en) | 2014-03-04 | 2019-03-12 | The Board Of Regents Of The University Of Texa System | Compositions and methods for enterohemorrhagic Escherichia coli (EHEC) vaccination |
CN108976289B (zh) * | 2015-11-20 | 2021-06-18 | 深圳市南山区人民医院 | 用于预防和治疗肠致病大肠杆菌感染的肽段 |
CN105821065A (zh) * | 2016-04-29 | 2016-08-03 | 南方医科大学 | 一种双抗原重组蛋白及其制备方法和应用 |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US20210054033A1 (en) * | 2018-01-25 | 2021-02-25 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for use of recombinant bacterial effector proteins as anti-inflammatory agents |
WO2019191409A1 (fr) * | 2018-03-29 | 2019-10-03 | Kimberly-Clark Worldwide, Inc. | Capteur pour indiquer un problème potentiel futur de la peau ou du tractus gastro-intestinal et procédés d'utilisation de celui-ci |
EP3962512A4 (fr) * | 2019-05-01 | 2023-01-18 | Innate Biologics LLC | Compositions et procédés immunomodulateurs |
CN113174389B (zh) * | 2021-05-27 | 2023-06-16 | 昆明理工大学 | 一种岷江百合诱导型启动子pr4及其应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4310550A (en) | 1979-10-26 | 1982-01-12 | Pfizer Inc. | Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
CA1247080A (fr) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Sequences d'acides amines ayant une activite antigenique |
US4744984A (en) | 1985-10-08 | 1988-05-17 | Vetrepharm Research, Inc. | Antiviral immunotherapeutic agent and preparation thereof |
US5151267A (en) | 1988-07-15 | 1992-09-29 | University Of Saskatchewan | Bovine herpesvirus type 1 polypeptides and vaccines |
SE9100556D0 (sv) * | 1991-02-26 | 1991-02-26 | Holmgren Jan | Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e coli bacteria in humans |
US5370989A (en) * | 1992-04-03 | 1994-12-06 | The Trustees Of Columbia University In The City Of New York | Solution for prolonged organ preservation |
RU2043771C1 (ru) * | 1993-02-25 | 1995-09-20 | Михаил Константинович Пирожков | Вакцина против эшерихиоза животных |
US5951988A (en) | 1993-03-30 | 1999-09-14 | University Of Saskatchewan | Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods |
DE69426051T2 (de) | 1993-07-30 | 2001-05-10 | Akzo Nobel Nv | Impfstoff für Geflügel |
AU5939396A (en) | 1995-06-07 | 1996-12-30 | Biolog, Inc. | Microbiological media for isolation and identification of en teric pathogens such as e. coli and salmonella |
FR2747394B1 (fr) | 1996-04-15 | 1998-07-03 | Rambach Alain | Milieu de culture pour la mise en evidence des bacteries e. coli enterohemorragiques, et procede pour sa mise en evidence |
CA2252372C (fr) | 1996-04-23 | 2010-06-29 | B. Brett Finlay | Proteine associee a un escherichia coli pathogene |
ATE489461T1 (de) | 1997-10-16 | 2010-12-15 | Univ Georgia | Transgene vögel und proteinproduktion |
JP4410412B2 (ja) | 1997-11-12 | 2010-02-03 | ザ ユニバーシティー オブ ブリティッシュ コロンビア | 病原菌のtir遺伝子によってコードされる、病原菌の宿主の膜受容体、hp90 |
US7208574B1 (en) | 1997-11-12 | 2007-04-24 | The University Of British Columbia | Host receptor for pathogenic bacteria |
US6365723B1 (en) * | 1998-12-04 | 2002-04-02 | Wisconsin Alumni Research Foundation | Sequences of E. coli O157 |
US20020132788A1 (en) | 2000-11-06 | 2002-09-19 | David Lewis | Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
US20020173478A1 (en) | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
NZ527322A (en) | 2001-01-04 | 2005-07-29 | Univ Saskatchewan | EHEC cell culture supernatant vaccine |
JP2002355074A (ja) | 2001-01-24 | 2002-12-10 | Univ Tsukuba | 腸管出血性病原性大腸菌o157:h7に特異的な核酸分子およびポリペプチド並びにこれらの使用方法 |
TWI350174B (en) * | 2003-03-12 | 2011-10-11 | Wyeth Corp | Adjuvanted bovine vaccines |
CN101711861A (zh) | 2003-10-31 | 2010-05-26 | 不列颠哥伦比亚大学 | 细菌毒力因子及其用途 |
-
2004
- 2004-10-29 CN CN200910206659A patent/CN101711861A/zh active Pending
- 2004-10-29 EP EP11175692A patent/EP2383287A1/fr not_active Withdrawn
- 2004-10-29 JP JP2006537022A patent/JP5100122B2/ja not_active Expired - Fee Related
- 2004-10-29 CN CN2004800395689A patent/CN1922324B/zh not_active Expired - Fee Related
- 2004-10-29 KR KR1020067010661A patent/KR101242445B1/ko not_active IP Right Cessation
- 2004-10-29 ZA ZA200604412A patent/ZA200604412B/xx unknown
- 2004-10-29 UA UAA200605985A patent/UA94206C2/ru unknown
- 2004-10-29 CA CA002543763A patent/CA2543763A1/fr not_active Abandoned
- 2004-10-29 KR KR1020117019259A patent/KR20110102956A/ko active IP Right Grant
- 2004-10-29 EP EP04789798A patent/EP1692287A4/fr not_active Withdrawn
- 2004-10-29 KR KR1020137001391A patent/KR20130018999A/ko not_active Application Discontinuation
- 2004-10-29 MX MXPA06004858A patent/MXPA06004858A/es active IP Right Grant
- 2004-10-29 AU AU2004286002A patent/AU2004286002B2/en not_active Ceased
- 2004-10-29 NZ NZ547156A patent/NZ547156A/en not_active IP Right Cessation
- 2004-10-29 EP EP11184778A patent/EP2462948A1/fr not_active Withdrawn
- 2004-10-29 WO PCT/CA2004/001891 patent/WO2005042746A1/fr active Application Filing
- 2004-10-29 US US10/577,742 patent/US8758771B2/en not_active Expired - Fee Related
- 2004-10-29 RU RU2006118803/10A patent/RU2465331C2/ru not_active IP Right Cessation
- 2004-10-29 BR BRPI0415816-4A patent/BRPI0415816A/pt not_active IP Right Cessation
- 2004-11-02 AR ARP040104025A patent/AR050050A1/es unknown
-
2006
- 2006-05-23 NO NO20062361A patent/NO20062361L/no not_active Application Discontinuation
-
2011
- 2011-04-27 AU AU2011201889A patent/AU2011201889B2/en not_active Ceased
- 2011-07-08 JP JP2011152074A patent/JP2011250790A/ja active Pending
- 2011-07-13 US US13/182,334 patent/US8507249B2/en not_active Expired - Fee Related
-
2012
- 2012-05-31 RU RU2012122559/10A patent/RU2012122559A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1922324A (zh) | 2007-02-28 |
AR050050A1 (es) | 2006-09-27 |
RU2012122559A (ru) | 2013-12-10 |
AU2011201889A1 (en) | 2011-05-19 |
RU2006118803A (ru) | 2007-12-10 |
KR20110102956A (ko) | 2011-09-19 |
NO20062361L (no) | 2006-07-20 |
EP2462948A1 (fr) | 2012-06-13 |
KR20130018999A (ko) | 2013-02-25 |
CN1922324B (zh) | 2010-06-09 |
JP2011250790A (ja) | 2011-12-15 |
CA2543763A1 (fr) | 2005-05-12 |
US20070041997A1 (en) | 2007-02-22 |
US8507249B2 (en) | 2013-08-13 |
AU2011201889B2 (en) | 2013-04-04 |
MXPA06004858A (es) | 2007-04-16 |
RU2465331C2 (ru) | 2012-10-27 |
BRPI0415816A (pt) | 2006-12-26 |
JP2007531511A (ja) | 2007-11-08 |
AU2004286002B2 (en) | 2011-01-27 |
US8758771B2 (en) | 2014-06-24 |
NZ547156A (en) | 2009-08-28 |
WO2005042746A1 (fr) | 2005-05-12 |
CN101711861A (zh) | 2010-05-26 |
AU2004286002A1 (en) | 2005-05-12 |
KR20070031848A (ko) | 2007-03-20 |
EP1692287A4 (fr) | 2007-03-28 |
EP1692287A1 (fr) | 2006-08-23 |
JP5100122B2 (ja) | 2012-12-19 |
KR101242445B1 (ko) | 2013-03-15 |
UA94206C2 (ru) | 2011-04-26 |
US20120064572A1 (en) | 2012-03-15 |
EP2383287A1 (fr) | 2011-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200604412B (en) | Bacterial virulence factors and uses thereof | |
IL173692A0 (en) | Bacterial strains, compositions including same and probiotic use thereof | |
GB0307026D0 (en) | Bacterial supplement | |
EP1664746A4 (fr) | Capteur d'antioxydants, procedes et compositions associes | |
EP1654374A4 (fr) | Processus et compositions de fermentation | |
EP1617807A4 (fr) | 1,4-diazepines substituees et leurs utilisations | |
EP1638977A4 (fr) | Salinosporamides et leurs methodes d'utilisation | |
IL174479A0 (en) | Hemiasterlin derivatives and uses thereof | |
IL171968A0 (en) | Difluoromethylbenzanilides and use thereof for combating micro-organisms, intermediate products and use thereof | |
HK1088837A1 (en) | Clk-peptide and slk-peptide | |
EP1674498A4 (fr) | Copolymere a blocs et utilisation | |
IL172704A0 (en) | Salinosporamides and methods for use thereof | |
IL165433A0 (en) | Bacterial transforming agent | |
GB0318546D0 (en) | Quinoxalinones and their use | |
SG119341A1 (en) | Novel bacterium and vaccine | |
GB0327907D0 (en) | Microorganism | |
GB0228691D0 (en) | Bacterial virulence genes | |
GB0305089D0 (en) | Composition, use and process | |
EP1660088A4 (fr) | Pyridomorphinanes, pyridazinomorphinanes et utilisation associee | |
AU2003210439A8 (en) | Pseudomonas virulence factors and uses thereof | |
AU2003284240A8 (en) | Probiotic bacteria | |
GB0308198D0 (en) | ADP-ribosylating bacterial toxin | |
GB0212423D0 (en) | Toxin Genes and uses thereof | |
GB0311164D0 (en) | Composition and use | |
GB0311167D0 (en) | Composition and use |